As pre-clinical data suggests that high circulating TSP-1 levels produced by tumor stroma may indirectly increase tumor perfusion while decreasing peritumoral and systemic blood flow, CD47-targeting mAbs are therefore likely to counteract these effects through regional stimulation of NO signaling (Isenberg et al., 2008b, 2009b). Here, CD47 is linked to neoplasm.